AbbVie to present new data from ADC platform at ESMO

AbbVie (ABBV) announced it will unveil new data from its robust antibody-drug conjugate platform at the 2025 European Society for Medical Oncology Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie’s portfolio such as telisotuzumab adizutecan, ABBV-706, and Emrelis in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options will be featured in multiple presentations. “Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs,” said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. “The compelling data we are sharing at ESMO showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio.” Key highlights: AbbVie will present three oral presentations for Temab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented: Combination with bevacizumab in Colorectal Cancer: In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy, treatment with 2.4 mg/kg dose of Temab-A plus Bev achieved an objective response rate of 26.7% compared to an ORR of 0% with trifluridine/tipiracil with Bev treatment emergent adverse events occurred in 67% and 65% of patients, respectively. Monotherapy in MET-Amplified Solid Tumors: Among 100 patients with advanced MET-amplified solid tumors, including non-small cell lung cancer, CRC, gastroesophageal adenocarcinoma, and 16 other tumor types who had progressed after SOC treatment, Temab-A monotherapy achieved an ORR of 46% across all dose levels and tumor types with higher responses observed in patients with NSCLC and GEA, The most common grade greater than or equal to TEAEs were anemia and neutropenia. Monotherapy in Pancreatic Ductal Adenocarcinoma: Among 42 biomarker unselected patients with advanced/metastatic PDAC who experienced disease progression while receiving or after completing their first-line therapy, Temab-A demonstrated an ORR of 24% overall and 40% in patients who received first-line gemcitabine-nab-paclitaxel treatment.3 Grade greater than or equal to TEAEs occurring in greater than or equal to10% of all patients were anemia and neutropenia.